Strong product growth, but revenue and EPS trail published Q2 expectations

The quarter missed the market’s financial bar despite strong growth. Published expectations were roughly $225 million of revenue and a $0.86 per-share loss; Axsome delivered $218.4 million and a $0.99 loss, making this a modest revenue miss and a wider-than-expected loss.

AUVELITY remains the core positive, with early Alzheimer’s-agitation traction supporting the growth story. AUVELITY sales rose 51% year over year to $180.3 million, while total prescriptions increased 12% sequentially to approximately 266,000. New-to-brand prescriptions among patients aged 65 and older rose 126% during the first eight weeks after the June launch, although that is an early adoption indicator rather than established recurring demand (Commercial Highlights — AUVELITY).

The earnings miss was largely an investment decision, not a collapse in demand. SG&A jumped 60% year over year to $208.1 million because of sales-force expansion and the Alzheimer’s-agitation and SYMBRAVO launches, while R&D fell to $46.2 million. That spending helped produce strong revenue growth, but it also left the company with a $51.3 million quarterly loss and only roughly flat cash year to date (Income Statement; Balance Sheet). The company reaffirmed that current cash should fund operations into cash-flow positivity, but provided no numerical profitability timetable (Financial Guidance).

Pipeline progress adds support, but most of it is milestone value rather than near-term earnings. The FDA accepted AXS-12’s NDA with a May 1, 2027 target action date, pediatric ADHD Phase 3 trials began, and Axsome expects ENGAGE binge-eating-disorder topline data in the fourth quarter of 2026 (Development Pipeline; Anticipated Milestones). These are constructive execution updates, but they do not offset the immediate financial miss; the net read is mixed, with commercial momentum intact but quarterly results below expectations.